Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Investigation of Pharmacokinetics, Safety and Tolerability of Oral Semaglutide (NNC0113-0217) in Subjects With Mild, Moderate and Severe Degrees of Hepatic Impairment Compared to Subjects With Normal Hepatic Function

NCT02016911 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT02016911
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02016911 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Investigation of Pharmacokinetics, Safety and Tolerability of Oral Semaglutide (NNC0113-0217) in Subjects With Mild, Moderate and Severe Degrees of Hepatic Impairment Compared to Subjects With Normal Hepatic Function
Lead sponsor
Novo Nordisk A/S
Phase
Phase 1
Overall status
Completed
Start date
December 12, 2013
Completion date
January 12, 2015
Enrollment
56 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes, diabetes mellitus, type 2, healthy